Document:

exv10w1

Exhibit 10.1

EMPLOYMENT AGREEMENT

     This AGREEMENT (the “Agreement”) is made as of September 15, 2008 (the “Effective Date”), by
and between EPIX Pharmaceuticals, Inc. (the “Employer”), and Kim C. Drapkin (the “Executive”). In
consideration of the mutual covenants contained in this Agreement, the Employer and the Executive
agree as follows:

     1. Employment. The Employer agrees to employ the Executive and the Executive agrees
to be employed by the Employer on the terms and conditions set forth in this Agreement.

     2. Capacity. The Executive shall initially serve the Employer as Chief Financial
Officer, subject to election by the Board of Directors of the Employer (the “Board of Directors”).
As Chief Financial Officer, the Executive shall have authority and responsibility for leading and
overseeing all finance and accounting activities of the Employer and, subject to the determination
of the Board of Directors, shall constitute an officer position pursuant to Section 16 of the
Securities Exchange Act of 1934, as amended. The Executive shall also serve the Employer in such
other or additional offices as the Executive may be requested to serve by the Board of Directors or
by the CEO. In such capacity or capacities, the Executive shall perform such services and duties
in connection with the business, affairs and operations of the Employer as may be assigned or
delegated to the Executive from time to time by or under the authority of the Board of Directors or
by the CEO. The Executive shall work at the Employer’s Lexington, Massachusetts office.

     3. Term. Subject to the provisions of Section 6, the Executive’s employment is “at
will” and may be terminated by either the Company or Executive for any reason, or for no reason, at
any time.

     4. Compensation and Benefits. The regular compensation and benefits payable to the
Executive under this Agreement shall be as follows:

          (a) Salary. For all services rendered by the Executive under this Agreement, the
Employer shall pay the Executive a salary (the “Salary”) at the annual rate of Two hundred and
sixty thousand dollars ($260,000), subject to increase from time to time in the discretion of the
Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation
Committee”). The Salary shall be payable in periodic installments in accordance with the
Employer’s usual practice for its senior executives.

          (b) Annual Bonus. Beginning with the fiscal year ending December 31, 2008, the
Executive shall be eligible for an annual bonus under terms established by the Board of Directors
or the Compensation Committee with such terms as may be established in the sole discretion of the
Board of Directors or Compensation Committee. Bonus payments for each fiscal year, as approved by
the Board of Directors or Compensation Committee, shall be paid between January 1 and March 15 of
the following fiscal year.

 

 

          (c) Incentive Bonus Payments. The Executive shall also be eligible to earn Incentive
Bonus Payments under the terms and conditions of the Incentive Bonus Plan attached hereto as
Exhibit B and incorporated herein by reference.

          (d) Situational Pay. Beginning with the fiscal quarter ending September 30, 2008, the
Executive shall also be entitled to receive situational pay in an amount not to exceed $50,000,
less applicable withholdings and deductions (“Situational Pay”). The Situational Pay shall be made
in four equal installments of $12,500 on the last payroll date in each of the Company’s fiscal
quarters in the one year period that follows the Effective Date (the “Award Payment Dates”),
provided that the Executive must be an active, full-time employee of the Employer on each
respective Award Payment Date to earn the applicable award payment If the Company terminates the
Executive’s employment without Cause pursuant to Section 6(c) below or as a result of disability
pursuant to Section 6(d) below, or if the Executive terminates her employment with Good Reason
pursuant to Paragraph 6(b) below, Executive shall receive a pro rata portion of the Situational Pay
installment for the fiscal quarter in which her employment ends and shall forfeit any remaining
unpaid Situation Pay. If Executive is terminated for Cause or terminates without Good Reason, she
will forfeit any unpaid Situational Pay.

          (e) Stock Options. In consideration of the covenants contained in this Agreement, the
Executive has received a grant of stock options in accordance with the Employer’s Stock Option Plan
and will continue to be eligible to receive stock option grants annually. All such grants shall be
subject to the terms and conditions of the Employer’s Stock Option Plan, and any relevant grant
agreement.

          (f) Regular Benefits. The Executive shall also be entitled to participate in any
employee benefit plans, medical insurance plans, life insurance plans, disability income plans,
retirement plans, expense reimbursement plans and other benefit plans which the Employer may from
time to time have in effect for all or most of its senior executives. Such participation shall be
subject to the terms of the applicable plan documents, generally applicable policies of the
Employer, applicable law and the discretion of the Board of Directors, the Compensation Committee
or any administrative or other committee provided for in or contemplated by any such plan. Nothing
contained in this Agreement shall be construed to create any obligation on the part of the Employer
to establish any such plan or to maintain the effectiveness of any such plan which may be in effect
from time to time.

          (g) Taxation of Payments and Benefits. The Employer shall undertake to make
deductions, withholdings and tax reports with respect to payments and benefits under this Agreement
to the extent that it reasonably and in good faith believes that it is required to make such
deductions, withholdings and tax reports. Payments under this Agreement shall be in amounts net of
any such deductions or withholdings. Nothing in this Agreement shall be construed to require the
Employer to make any payments to compensate the Executive for any adverse tax effect associated
with any payments or benefits or for any deduction or withholding from any payment or benefit.

          (h) Reimbursement of Legal Fees. The Employer shall reimburse the Executive for up to
$5,000 in legal fees incurred in connection with the negotiation and drafting of this Agreement.

2

 

     5. Extent of Service. During the Executive’s employment under this Agreement, the
Executive shall, subject to the direction and supervision of the Board of Directors or the Chief
Executive Officer, devote the Executive’s full business time, best efforts and business judgment,
skill and knowledge to the advancement of the Employer’s interests and to the discharge of the
Executive’s duties and responsibilities under this Agreement. The Executive shall not engage in
any other business activity, including service as a director, board member or consultant to any
other entity, except as may be approved in advance, in writing, by the Board of Directors; provided
that nothing in this Agreement shall be construed as preventing the Executive from:

          (a) investing the Executive’s assets in any company or other entity in a manner not prohibited
by Section 7(d) and in such form or manner as shall not require any material activities on the
Executive’s part in connection with the operations or affairs of the companies or other entities in
which such investments are made; or

          (b) engaging in religious, charitable or other community or non-profit activities that do not
impair the Executive’s ability to fulfill the Executive’s duties and responsibilities under this
Agreement.

     6. Termination and Termination Benefits. The Executive’s employment under this
Agreement shall terminate under the following circumstances set forth in this Section 6.

          (a) Termination by the Employer for Cause. The Executive’s employment under this
Agreement may be terminated for Cause without further liability on the part of the Employer
effective immediately upon a vote of the Board of Directors and written notice to the Executive.
Only the following shall constitute “Cause” for such termination:

          (i) dishonesty of the Executive that is material to the business of the Employer;

          (ii) the commission or indictment of the Executive for (A) a felony or (B) any
misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

          (iii) material failure to perform to the reasonable satisfaction of the Board of
Directors a substantial portion of the Executive’s duties and responsibilities assigned or
delegated under this Agreement, which failure continues, in the reasonable judgment of the
Board of Directors, for at least thirty (30) days after written notice given to the
Executive by the Board of Directors or the Chief Executive Officer;

          (iv) gross negligence, willful misconduct or insubordination of the Executive with
respect to the Employer or any affiliate of the Employer; or

          (v) material breach by the Executive of any of the Executive’s obligations under this
Agreement.

          (b) Termination by the Executive. The Executive’s employment under this Agreement may
be terminated by the Executive without Good Reason (as defined below) by written notice to the
Board of Directors at least sixty (60) days prior to such termination. The Executive’s employment
under this Agreement may be terminated by the Executive with Good

3

 

Reason at any time. For the purposes of this Agreement, Good Reason shall mean that the
Executive has complied with the “Good Reason Process” (hereinafter defined) following the
occurrence of any of the following events: (i) a material reduction of the Executive’s
responsibilities, duties or authority, (ii) a material reduction in the Executive’s Salary, or
(iii) the relocation of the Executive’s primary place of employment to a location more than 100
miles from Lexington, Massachusetts. “Good Reason Process” shall mean that (1) the Executive
reasonably determines in good faith that a “Good Reason” condition has occurred; (2) the Executive
notifies the Employer in writing of the occurrence of the Good Reason condition within 60 days of
the occurrence of such condition; (3) the Executive cooperates in good faith with the Employer’s
efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy
the condition; (4) notwithstanding such efforts, the Good Reason condition continues to exist; and
(5) the Executive terminates her employment within 60 days after the end of the Cure Period. If
the Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed
not to have occurred.

          (c) Termination by the Employer Without Cause. Subject to the payment of Termination
Benefits pursuant to Section 6(d), the Executive’s employment under this Agreement may be
terminated by the Employer without Cause upon 30 days’ written notice to the Executive. The
Executive’s employment shall not be considered to be terminated without Cause if the Executive’s
employment terminates by reason of death or disability pursuant to Section 6(e).

          (d) Certain Termination Benefits. Unless otherwise specifically provided in this
Agreement or otherwise required by law, all compensation and benefits payable to the Executive
under this Agreement shall terminate on the date of termination of the Executive’s employment under
this Agreement. Notwithstanding the foregoing, in the event of termination of the Executive’s
employment with the Employer pursuant to Section 6(c) above or termination by the Executive with
Good Reason pursuant to Section 6(b) above, the Employer shall provide to the Executive the
following termination benefits (“Termination Benefits”), provided that the Executive executes (and
does not revoke) a general release of claims (the “Release”) in substantially the form attached
hereto as Exhibit A, with such modifications as may be required at the time of execution for a
valid and enforceable general release of claims, within the time frame set forth in the Release:

          (i) a lump sum equal to twelve (12) months Salary (at the rate then in effect pursuant
to Section 4(a)), payable in the next regular pay period that occurs more than 30 days
following the date of termination of the Executive’s employment under this Agreement; and

          (ii) continuation of group health plan benefits to the extent authorized by and
consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the
regular premium for such benefits shared in the same relative proportion by the Employer and
the Executive as in effect on the date of termination until twelve (12) months after the
date of termination. Notwithstanding the foregoing, nothing in this Section 6(d) shall be
construed to affect the Executive’s right to receive COBRA continuation entirely at the
Executive’s own cost to the extent that the Executive may

4

 

continue to be entitled to COBRA continuation after the Executive’s right to cost
sharing under Section 6(d)(ii) ceases; and

          (iii) that portion of her bonus as had been accrued by the Employer in accordance with
generally accepted accounting principles as of the end of the fiscal quarter immediately
preceding such termination. This portion of the bonus will be paid to the Executive at the
time the Employer pays bonuses to other senior employees, provided that it shall be paid no
later than March 14 of the calendar year immediately following the calendar year during
which termination of employment occurs.  

          (iv) a pro rata portion of the installment of the Situational Pay for the fiscal
quarter in which the Executive’s employment is terminated, payable in the next regular pay
period that occurs more than 30 days following the date of termination of the Executive’s
employment.

          (v) any Incentive Bonus Separation Payment due to the Executive pursuant to the terms
of Exhibit B to this Agreement.

          (vi) If the Release is not executed (without revocation) within the time provided in
the Release, or the Executive violates any provision of Section 7, below, the Executive
shall forfeit all rights to any Termination Benefits under this Agreement.

          (e) Disability. The Employer may terminate the Executive’s employment if she is
disabled and unable to perform the essential functions of the Executive’s then existing position or
positions under this Agreement with or without reasonable accommodation for a period of 180 days
(which need not be consecutive) in any 12-month period. Until the Executive’s employment is
terminated, the Executive will continue to receive payment from the Employer, which when added to
any sick pay or disability pay, shall equal her Salary. Upon such termination, the Executive shall
be entitled to receive a pro rata share of her bonus for the fiscal year in which termination
occurs pursuant to Section 4(b) above and a pro rata share of her Situational Bonus for the fiscal
quarter in which such termination occurs pursuant to Section 4(d) above. This pro rata bonus shall
be paid to the Executive at the time the Employer pays bonuses to other senior employees, provided
that it shall be paid no later than March 14 of the calendar year immediately following the
calendar year during which termination of employment occurs.

     If any question shall arise as to whether during any period the Executive is disabled so as to
be unable to perform the essential functions of the Executive’s then existing position or positions
with or without reasonable accommodation, the Executive may, and at the request of the Employer
shall, submit to the Employer a certification in reasonable detail by a physician selected by the
Employer to whom the Executive or the Executive’s guardian has no reasonable objection as to
whether the Executive is so disabled or how long such disability is expected to continue, and such
certification shall for the purposes of this Agreement be conclusive of the issue. The Executive
shall cooperate with any reasonable request of the physician in connection with such certification.
If such question shall arise and the Executive shall fail to submit such certification, the
Employer’s determination of such issue shall be binding on the Executive. Nothing in this Section
shall be construed to waive the Executive’s rights, if any, under existing

5

 

law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et
seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq

     7. Confidential Information, Noncompetition and Cooperation.

          (a) Confidential Information. As used in this Agreement, “Confidential Information”
means information belonging to the Employer which is of value to the Employer in the course of
conducting its business and the disclosure of which could result in a competitive or other
disadvantage to the Employer. Confidential Information includes, without limitation, financial
information, reports, and forecasts; inventions, improvements and other intellectual property;
trade secrets; know-how; designs, processes or formulae; software; market or sales information or
plans; customer lists; and business plans, prospects and opportunities (such as possible
acquisitions or dispositions of businesses or facilities) which have been discussed or considered
by the management of the Employer. Confidential Information includes information developed by the
Executive in the course of the Executive’s employment by the Employer, as well as other information
to which the Executive may have access in connection with the Executive’s employment. Confidential
Information also includes the confidential information of others with which the Employer has a
business relationship. Notwithstanding the foregoing, Confidential Information does not include
information in the public domain, unless due to breach of the Executive’s duties under Section
7(b).

          (b) Confidentiality. The Executive understands and agrees that the Executive’s
employment creates a relationship of confidence and trust between the Executive and the Employer
with respect to all Confidential Information. At all times, both during the Executive’s employment
with the Employer and after its termination, the Executive will keep in confidence and trust all
such Confidential Information, and will not use or disclose any such Confidential Information
without the written consent of the Employer, except as may be necessary in the ordinary course of
performing the Executive’s duties to the Employer.

          (c) Documents, Records, etc. All documents, records, data, apparatus, equipment and
other physical property, whether or not pertaining to Confidential Information, which are furnished
to the Executive by the Employer or are produced by the Executive in connection with the
Executive’s employment will be and remain the sole property of the Employer. The Executive will
return to the Employer all such materials and property as and when requested by the Employer. In
any event, the Executive will return all such materials and property immediately upon termination
of the Executive’s employment for any reason. The Executive will not retain with the Executive any
such material or property or any copies thereof after such termination.

          (d) Noncompetition and Nonsolicitation. During the Executive’s employment with the
Company and for one year thereafter (or, if longer, for the number of months’ salary paid as
severance, as defined in Section 6(d)(i)), the Executive will not, directly or indirectly, whether
as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage,
participate, assist or invest in any Competing Business (as hereinafter defined). During the
Executive’s employment with the Company and for two years thereafter, the Executive (i) will
refrain from attempting to employ, recruiting or otherwise soliciting, inducing or influencing any
person to leave employment with the Employer (other than terminations of employment of

6

 

subordinate employees undertaken in the course of the Executive’s employment with the
Employer); and (ii) will refrain from soliciting or encouraging any customer or supplier to
terminate or otherwise modify adversely its business relationship with the Employer. The Executive
understands that the restrictions set forth in this Section 7(d) are intended to protect the
Employer’s interest in its Confidential Information and established employee, customer and supplier
relationships and goodwill, and agrees that such restrictions are reasonable and appropriate for
this purpose. For purposes of this Agreement, the term “Competing Business” shall mean a business
with a primary focus on discovering drugs targeting GPCR’s through the use of in silico discovery
and development technologies. Notwithstanding the foregoing, the Executive may own up to one
percent (1%) of the outstanding stock of a publicly held corporation which constitutes or is
affiliated with a Competing Business.

          (e) Third-Party Agreements and Rights. The Executive hereby confirms that the
Executive is not bound by the terms of any agreement with any previous employer or other party
which restricts in any way the Executive’s use or disclosure of information or the Executive’s
engagement in any business. The Executive represents to the Employer that the Executive’s
execution of this Agreement, the Executive’s employment with the Employer and the performance of
the Executive’s proposed duties for the Employer will not violate any obligations the Executive may
have to any such previous employer or other party. In the Executive’s work for the Employer, the
Executive will not disclose or make use of any information in violation of any agreements with or
rights of any such previous employer or other party, and the Executive will not bring to the
premises of the Employer any copies or other tangible embodiments of non-public information
belonging to or obtained from any such previous employment or other party.

          (f) Litigation and Regulatory Cooperation. During and after the Executive’s
employment, the Executive shall cooperate fully with the Employer in the defense or prosecution of
any claims or actions now in existence or which may be brought in the future against or on behalf
of the Employer which relate to events or occurrences that transpired while the Executive was
employed by the Employer. The Executive’s full cooperation in connection with such claims or
actions shall include, but not be limited to, being available to meet with counsel to prepare for
discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times.
During and after the Executive’s employment, the Executive also shall cooperate fully with the
Employer in connection with any investigation or review of any federal, state or local regulatory
authority as any such investigation or review relates to events or occurrences that transpired
while the Executive was employed by the Employer. The Employer shall reimburse the Executive for
any reasonable out-of-pocket expenses and time (at a mutually agreed upon rate) incurred in
connection with the Executive’s performance of obligations pursuant to this Section 7(f).

          (g) Injunction. The Executive agrees that it would be difficult to measure any
damages caused to the Employer which might result from any breach by the Executive of the promises
set forth in this Section 7, and that in any event money damages would be an inadequate remedy for
any such breach. Accordingly, subject to Section 8 of this Agreement, the Executive agrees that if
the Executive breaches, or proposes to breach, any portion of this Agreement, the Employer shall be
entitled, in addition to all other remedies that it may have, to

7

 

an injunction or other appropriate
equitable relief to restrain any such breach, without showing or proving any actual damage to the
Employer.

     8. Arbitration of Disputes. Any controversy or claim arising out of this Agreement
or the breach thereof shall, to the fullest extent permitted by law, be settled by arbitration in
any forum and form agreed upon by the parties or, in the absence of such an agreement, under the
auspices of the American Arbitration Association (“AAA”) in Boston, Massachusetts in accordance
with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules
and procedures applicable to the selection of arbitrators. In the event that any person or entity
other than the Executive or the Employer may be a party with regard to any such controversy or
claim, such controversy or claim shall be submitted to arbitration subject to such other person or
entity’s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court
having jurisdiction thereof. This Section 8 shall be specifically enforceable. Notwithstanding the
foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole
purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in
which such relief is appropriate; provided that any other relief shall be pursued through an
arbitration proceeding pursuant to this Section 8.

     9. Consent to Jurisdiction. To the extent that any court action is permitted
consistent with or to enforce Section 8 of this Agreement, the parties hereby consent to the
jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States
District Court for the District of Massachusetts. Accordingly, with respect to any such court
action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to
service of process; and (c) waives any other requirement (whether imposed by statute, rule of
court, or otherwise) with respect to personal jurisdiction or service of process.

     10. Integration. This Agreement, together with any stock option plans and grants,
constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements between the parties with respect to any related subject matter.

     11. Section 409A.

          (a) Anything in this Agreement to the contrary notwithstanding, if at the time of the
Executive’s separation from service within the meaning of Section 409A of the Internal Revenue Code
of 1986, as amended, and the regulations thereunder (the “Code”), the Employer determines that the
Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code,
then to the extent any payment or benefit that the Executive becomes entitled to under this
Agreement would be considered deferred compensation subject to the 20 percent additional tax
imposed pursuant to Section 409A(a) of the Code as a result of the application of Section
409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be
provided until the date that is the earlier of (A) six months and one day after the Executive’s
separation from service, or (B) the Executive’s death. The determination of whether and when a
separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-1(h).

          (b) The parties intend that this Agreement will be administered in accordance with Section
409A of the Code. To the extent that any provision of this Agreement is ambiguous

8

 

as to its
compliance with Section 409A of the Code, the provision shall be read in such a manner so that all
payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may
be amended, as reasonably requested by either party, and as may be
necessary to fully comply with Section 409A of the Code and all related rules and regulations
in order to preserve the payments and benefits provided hereunder without additional cost to either
party.

          (c) The Employer makes no representation or warranty and shall have no liability to the
Executive or any other person if any provisions of this Agreement are determined to constitute
deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or
the conditions of, such Section.

     12. Assignment; Successors and Assigns. Neither the Employer nor the Executive may
make any assignment of this Agreement or any interest herein, by operation of law or otherwise,
without the prior written consent of the other party; provided that the Employer may assign its
rights under this Agreement without the consent of the Executive in the event that the Employer
shall effect a reorganization, consolidate with or merge into any other corporation, partnership,
organization or other entity, or transfer all or substantially all of its properties or assets to
any other corporation, partnership, organization or other entity. This Agreement shall inure to
the benefit of and be binding upon the Employer and the Executive, their respective successors,
executors, administrators, heirs and permitted assigns.

     13. Enforceability. If any portion or provision of this Agreement (including, without
limitation, any portion or provision of any section of this Agreement) shall to any extent be
declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this
Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion
and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law.

     14. Waiver. No waiver of any provision hereof shall be effective unless made in
writing and signed by the waiving party. The failure of any party to require the performance of
any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a
waiver of any subsequent breach.

     15. Notices. Any notices, requests, demands and other communications provided for by
this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally
recognized overnight courier service or by registered or certified mail, postage prepaid, return
receipt requested, to the Executive at the last address the Executive has filed in writing with the
Employer or, in the case of the Employer, at its main offices, attention of the Chief Executive
Officer, and shall be effective on the date of delivery in person or by courier or three (3) days
after the date mailed.

     16. Amendment. This Agreement may be amended or modified only by a written instrument
signed by the Executive and by a duly authorized representative of the Employer.

9

 

     17. Governing Law. This is a Massachusetts contract and shall be construed under and
be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect
to the conflict of laws principles of such Commonwealth. With respect to any
disputes concerning federal law, such disputes shall be determined in accordance with the law
as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

     18. Counterparts. This Agreement may be executed in any number of counterparts, each
of which when so executed and delivered shall be taken to be an original; but such counterparts
shall together constitute one and the same document.

     IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer,
by its duly authorized officer, and by the Executive, as of the Effective Date.

	 	 	 	 	 
	 	 	EPIX PHARMACEUTICALS, INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Elkan Gamzu
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	/s/ Kim C. Drapkin
	 	 	 
	 	 	Executive

10

 

Exhibit A

RELEASE AGREEMENT

          For and in consideration of the mutual agreements and promises contained in the Employment
Agreement, dated                      (the “Employment Agreement”) between KIM C. DRAPKIN (“Executive”) and
EPIX PHARMACEUTICALS, INC.(“the Company”), and other good and valuable consideration, the
Executive, for herself and her successors, assigns, heirs, executors and administrators, hereby
fully and unconditionally releases and forever discharges the Company, including its shareholders,
subsidiaries, affiliates, officers, directors, employees, agents, and attorneys (collectively the
“Releasees”) of and from any and all claims, causes of action, suits, obligations, demands, debts,
agreements, promises, liabilities, controversies, costs, damages, expenses and attorneys’ fees, of
any kind and character, whether based on any federal, state, or local law or right of action, at
law or in equity, including without limitation claims arising under Title VII of the Civil Rights
Act, the Americans with Disabilities Act, the Age Discrimination in Employment Act, Massachusetts
General Laws Chapter 151B, or any other applicable federal state or local employment discrimination
statute, regulation, or ordinance prohibiting discrimination on the basis of age, race, sex,
national origin, religion, sexual preference, disability, veteran status, genetic information or
any other protected characteristic, whether accrued or unaccrued, whether known or unknown, and
whether direct or contingent, which Executive claimed or could have claimed against any of the
Releasees, from the beginning of time through and including the date Executive signs this Release.
This Release includes, without implication of limitation, the complete release of all claims of or
for: breach of express or implied contract; wrongful termination of employment whether in contract
or tort; intentional, reckless, or negligent infliction of emotional distress; breach of any
express or implied covenant of employment, including the covenant of good faith and fair dealing;
interference with contractual or advantageous relations, whether prospective or existing; deceit or
misrepresentation; discrimination or retaliation under state, federal, or municipal law, including,
without implication of limitation, defamation or damage to reputation; reinstatement; punitive or
emotional distress damages; wages, severance pay, vacation pay, back or front pay or other forms of
compensation; and attorney’s fees and costs. Executive understands that this general release of
claims extends to any and all claims related to Executive’s employment by the Company and
Executive’s separation from employment.

     This Release of Claims is intended to comply with the Older Workers Benefit Protection Act of
1990 with regard to the release of claims under the Age Discrimination in Employment Act.
Executive hereby acknowledges and agrees:

     (a) Executive is specifically waiving rights and claims under the ADEA. Such waiver of rights
does not extend to any rights or claims under the ADEA arising after the date Executive executes
this Release;

     (c) Executive has been advised to consult with an attorney of her choice before executing this
Release;

11

 

     (d) Executive would not be entitled to certain termination benefits under the Employment
Agreement but for her execution of this Release;

     (e) Executive has read this Release, understands its terms, and has executed it voluntarily
and without coercion of any kind;

     (f) Executive has been provided twenty-one (21) days to consider this Release before signing
it (“Consideration Period”). If the Executive elects to sign this Release in fewer than 21 days,
Executive represents that he has voluntarily elected to waive the remaining Consideration Period in
order to avail herself of the termination benefits under her Employment Agreement more quickly.
Executive also has the right to revoke her agreement to this Release within seven (7) days after
signing it (“Revocation Period”). Such revocation must be in writing delivered during the
Revocation Period to                      at fax number                     ;

     (g) Any severance or related payments owed to Executive under Section 6 of the Employment
Agreement will only be made by the Company after the Revocation Period has elapsed without the
Executive having revoked this Release.

     Nothing in this Release is intended to release the Company from any rights the Executive may
have to indemnification from the Company for conduct within the scope of her duties during her
employment, including without limitation such indemnification as may be provided in the Company
By-Laws, through a directors’ and officers’ liability insurance policy, or such other contractual
or common law indemnification rights as may exist.

     Executive hereby reaffirms all of her post-employment, confidentiality, noncompetition and
cooperation obligations set forth in Section 7 of the Employment Agreement. Executive further
agrees not to make any disparaging statements or remarks, whether orally or in writing, concerning
or relating to the Company or any of the Releasees (in their official and personal capacities), its
and their services and/or products. In addition, Executive shall not take any actions or conduct
herself in any way that would reasonably be expected to affect adversely the reputation or good
will of the Company or any of the Releasees.

     This Release shall not be construed as an admission by the Company or any other Releasee of
any improper, discriminatory or unlawful action against the Executive.

	 	 	 
	 
	 

	 	 
	 

	 	Name: Kim C. Drapkin

12

 

Exhibit B

INCENTIVE BONUS PLAN

This agreement sets forth the terms of an Incentive bonus plan (the “Incentive Bonus Plan”) under
which you will be entitled to receive certain distributions of the common stock of EPIX
Pharmaceuticals, Inc. (the “Company”) and certain monetary payments as specified below
(collectively the “Incentive Bonus Payments”) if you remain employed by the Company for a certain
period of time and/or until certain events occur, as specified below, provided that you fully
satisfy each of the Incentive Bonus Requirements set forth below.

	 	•	 	Provided that you remain an active, full-time employee of the Company from the Effective
Date set forth in the accompanying Employment Agreement between you and the Company (the
“Employment Agreement”) through December 31, 2008, the Company shall grant you a bonus in
the form of fully vested shares of the Company’s common stock with a fair market value
equal to 25% of your gross annual base salary as of December 31, 2008. The Company intends
to meet its minimum tax withholding obligation by withholding from shares of the Company’s
common stock to be issued to you. The fair market value of the Company’s common stock for
purposes of this grant will be determined based on the closing price of the Company’s
common stock on December 31, 2008 or, if not a trading day, then the immediately preceding
trading day. (For example, if your gross annual base salary on December 31, 2008 is
$100,000 and the closing price of the Company’s stock on December 31, 2008 is $1 per share,
then you would receive 25,000 shares of the Company’s stock, less any shares the Company
withholds to meet its minimum tax obligations.) This grant shall be made on December 31,
2008.
	 
	 	•	 	Provided that you remain an active, full-time employee of the Company from the Effective
Date of the Employment Agreement through June 30, 2009, the Company shall grant you a bonus
in the form of fully vested shares of the Company’s common stock with a fair market value
equal to 25% of your gross annual base salary as of June 30, 2009. The Company intends to
meet its minimum tax withholding obligation by withholding from shares of the Company’s
common stock to be issued to you. The fair market value of the Company’s common stock for
purposes of this grant will be determined based on the closing price of the Company’s
common stock on June 30, 2009 of, if not a trading day, then the immediately preceding
trading day. (For example, if your gross annual base salary on June 30, 2009 is $100,000
and the closing price of the Company’s stock on June 30, 2009 is $1 per share, then you
would receive 25,000 shares of the Company’s stock, less any shares the Company withholds
to meet its minimum tax obligations.) This grant shall be made on June 30, 2009.
	 
	 	•	 	Provided that you remain an active, full-time employee of the Company from the Effective
Date of the Employment Agreement through the date when the Company has completed its goal
of raising “New Funds,” the Company shall pay you a lump sum in

13

 

	 	 	 	cash equal to 25% of your gross annual base salary as of that date, less applicable
deductions and withholdings. For purposes of this Incentive Bonus Plan, “New Funds” shall
mean aggregate gross proceeds to the Company of at least $25 million from one or more sales
of debt, equity or equity-linked securities of the Company or committed funds from a newly
executed collaboration or licensing agreement on or after July 1, 2008. For the avoidance
of doubt, you will not earn this payment, or any portion thereof, unless you are an active
employee on the date on which the New Funds have been raised in entirety. This payment
shall be made to you no later than the Company’s first payroll date following the date the
Company has determined that all of the New Funds have been raised and received by the
Company.
	 
	 	•	 	Provided that you remain an active, full-time employee of the Company from the Effective
Date of the Employment Agreement through the date when the Company receives written
notification of approval for Vasovist from the United States Food and Drug Administration
(the “Approval Date”), the Company shall pay you a lump sum in cash equal to 25% of your
gross annual base salary as of that date, less applicable deductions and withholdings. You
will not earn this payment, or any portion thereof, unless you are an active employee when
the Approval Date occurs. This payment shall be made no later than the Company’s first
payroll date following the Approval Date.
	 
	 	•	 	Notwithstanding the foregoing, in the event your employment is terminated on or before
June 30, 2009, by the Company without Cause (as defined in Section 6(a) of the Employment
Agreement), or as a result of your resignation of your employment with Good Reason (as
defined in Section 6(b) of the Employment Agreement), the Company shall provide you with
any and all of the Incentive Bonus Payments set forth above that you have not received as
of the last day of your employment (the “Separation Date”) , regardless of whether the
applicable dates or milestones set forth above have been achieved and provided you enter
into and do not revoke a Release (as defined in the Section 6(d) of the Employment
Agreement) (“Incentive Bonus Separation Payments”). These Incentive Bonus Separation
Payments shall be based on your gross annual base salary and/or on the fair market value of
the Company’s common stock as of the Separation Date (or, if that date is not a trading
day, then the distributions shall be based on the fair market value of the Company’s common
stock as of the most recent trading day prior to the Separation Date ). At its discretion,
the Company’s Board of Directors may decide that the Incentive Bonus Separation Payments
shall be made entirely as a lump sum cash distribution. (For example, if as of the
Separation Date , you have not received either of the Incentive Bonus Payments that are to
be made in the form of shares of the Company’s stock under the terms set forth above, the
Company’s Board of Directors may in its discretion decide that you are entitled to a lump
sum cash distribution of 50% of your then gross annual base salary rather than a
distribution of shares of the Company’s stock with a fair market value equal to 50% of your
then gross annual base salary). These Incentive Bonus Separation Payments shall be made no
later than the Company’s first payroll date following the Separation Date . For the
avoidance of doubt, nothing in this Incentive Bonus Plan shall be construed to entitle you
to receive any one of the payments or grants that comprise the Incentive Bonus Payments
more than once.

14

 

The Company shall undertake to make deductions, withholdings and tax reports with respect to the
Incentive Bonus Payments to the extent that it reasonably and in good faith believes that it is
required to make such deductions, withholdings and tax reports. Incentive Bonus Payments shall be
in amounts net of any such deductions or withholdings. Except to the extent otherwise specified,
nothing in this Incentive Bonus Plan shall be construed to require the Company to make any payments
to compensate you for any adverse tax effect associated with the Incentive Bonus Payments or for
any deduction or withholding from any payment or benefit.

To be eligible for the Incentive Bonus Payments set forth above, you must meet the following
requirements (the “Incentive Bonus Requirements”):

	 	•	 	You must remain an active, full-time employee of the Company from the date of the
Employment Agreement through the applicable date(s), except if you are terminated by the
Company without Cause or you resign for Good Reason as specifically set forth above, and
	 
	 	•	 	You are required to comply with the terms of the Employment Agreement.

15exv10w2

Exhibit 10.2

AMENDMENT TO EMPLOYMENT AGREEMENT

     This Amendment to Employment Agreement (this “Amendment”) is made as of the 16th day
of September, 2008 by and between Chen Schor (the “Executive”) and EPIX Pharmaceuticals, Inc. (the
“Employer”).

     WHEREAS, the Executive and the Employer entered into an Employment Agreement as of June 16,
2008 (the “Original Agreement”);

     WHEREAS, the parties desire to amend certain provisions of the Original Agreement in
accordance with Section 16 thereof.

     NOW, THEREFORE, the Executive and the Employer, each intending to be legally bound hereby, do
mutually covenant and agree as follows:

     1. Section 4 of the Original Agreement is hereby amended by adding the following new
subsection (g) immediately after subsection (f) thereof:

          “g. Retention Bonus Plan. If the Executive remains employed by the Employer for a
certain period of time and/or until the occurrence of certain events, as specified below, the
Executive will be entitled to certain distributions of the Employer’s common stock and certain
monetary payments as specified below (collectively the “Retention Bonus Payments”) provided that
the Executive fully satisfies each of the Retention Bonus Requirements set forth below.

	 	•	 	Provided that the Executive remains an active, full-time employee of the Employer from
the date of this Agreement as amended through December 31, 2008, the Employer shall grant
the Executive a bonus in the form of fully vested shares of the Employer’s common stock
with a fair market value equal to 25% of the Executive’s gross annual base salary as of
December 31, 2008. The Employer intends to meet its minimum tax withholding obligation by
withholding from shares of the Employer’s common stock to be issued to the Executive with
the exception of federal tax to be deducted at no less than 35%. The fair market value of
the Employer’s common stock for purposes of this grant will be determined based on the
closing price of the Employer’s common stock on December 31, 2008 or, if not a trading day,
then the immediately preceding trading day. (For example, if the Executive’s gross annual
base salary on December 31, 2008 is $100,000 and the closing price of the Employer’s stock
on December 31, 2008 is $1 per share, then the Executive would receive 25,000 shares of the
Employer’s stock, less any shares the Employer withholds to meet its minimum tax
obligations.) This grant shall be made on December 31, 2008.
	 
	 	•	 	Provided that the Executive remain an active, full-time employee of the Employer from
the date of this Agreement as amended through June 30, 2009, the Employer shall grant the
Executive a bonus in the form of fully vested shares of the Employer’s common stock with a
fair market value equal to 25% of the Executive’s gross annual base salary as of June 30,
2009. The Employer intends to meet its minimum tax withholding obligation by

 

 

	 	 	 	withholding from shares of the Employer’s common stock to be issued to the Executive with
the exception of federal tax to be deducted at no less than 35%. The fair market value of
the Employer’s common stock for purposes of this grant will be determined based on the
closing price of the Employer’s common stock on June 30, 2009 of, if not a trading day, then
the immediately preceding trading day. (For example, if the Executive’s gross annual base
salary on June 30, 2009 is $100,000 and the closing price of the Employer’s stock on June
30, 2009 is $1 per share, then the Executive would receive 25,000 shares of the Employer’s
stock, less any shares the Employer withholds to meet its minimum tax obligations.) This
grant shall be made on June 30, 2009.
	 
	 	•	 	Provided that the Executive remain an active, full-time employee of the Employer from
the date of this Agreement as amended through the date when the Employer has completed its
goal of raising “New Funds,” the Employer shall pay the Executive a lump sum in cash equal
to 25% of the Executive’s gross annual base salary as of that date, less applicable
deductions and withholdings. For purposes of this Section 6(g), “New Funds” shall mean
aggregate gross proceeds to the Employer of at least $25 million from one or more sales of
debt, equity or equity-linked securities of the Employer or committed funds from a newly
executed collaboration or licensing agreement on or after July 1, 2008. For the avoidance
of doubt, the Executive will not earn this payment, or any portion thereof, unless the
Executive is an active employee on the date on which the New Funds have been raised in
entirety. This payment shall be made to the Executive no later than the Employer’s first
payroll date following the date the Employer has determined that all of the New Funds have
been raised and received by the Employer.
	 
	 	•	 	Provided that the Executive remain an active, full-time employee of the Employer from
the date of this Agreement as amended through the date when the Employer receives written
notification of approval for Vasovist from the United States Food and Drug Administration
(the “Approval Date”), the Employer shall pay the Executive a lump sum in cash equal to 25%
of the Executive’s gross annual base salary as of that date, less applicable deductions and
withholdings. The Executive will not earn this payment, or any portion thereof, unless the
Executive is an active employee when the Approval Date occurs. This payment shall be made
no later than the Employer’s first payroll date following the Approval Date.
	 
	 	•	 	Notwithstanding the foregoing, in the event the Executive’s employment is terminated by
the Employer as a result of a Change in Control and without Cause (as defined in Section
6(a) of this Agreement) or the Executive resigns from the Executive’s employment with Good
Reason (as defined in Section 6(b) of this Agreement) following a Change in Control but
prior to June 30, 2009 (the “Change in Control Separation Date”), the Employer shall
provide the Executive with any and all of the Retention Bonus Payments set forth above that
the Executive has not received as of the Change in Control Separation Date regardless of
whether the applicable dates or milestones set forth above have been achieved (the “Change
in Control Payments”). These Change in Control Payments shall be based on the Executive’s
gross annual base salary and/or on the fair market value of the Employer’s common stock as
of the Change in Control Separation Date (or, if the Change in Control Separation Date is
not a trading day, then the distributions shall be

2

 

	 	 	 	based on the fair market value of the Employer’s common stock as of the most recent trading
day prior to the Change in Control Separation Date). At its discretion, the Employer’s
Board of Directors may decide that the Change in Control Payments shall be made entirely as
a lump sum cash distribution. (For example, if as of the Change in Control Separation Date
the Executive has not received either of the Retention Bonus Payments that are to be made in
the form of shares of the Employer’s stock under the terms set forth above, the Employer’s
Board of Directors may in its discretion decide that the Executive is entitled to a lump sum
cash distribution of 50% of the Executive’s then gross annual base salary rather than a
distribution of shares of the Employer’s stock with a fair market value equal to 50% of the
Executive’s then gross annual base salary). These Change in Control Payments shall be made
no later than the Employer’s first payroll date following the Change in Control Separation
Date. For the avoidance of doubt, nothing in this Section 6(g) shall be construed to
entitle the Executive to receive any one of the payments or grants that comprise the
Retention Bonus Payments more than once.

The Employer shall undertake to make deductions, withholdings and tax reports with respect to the
Retention Bonus Payments to the extent that it reasonably and in good faith believes that it is
required to make such deductions, withholdings and tax reports. Retention Bonus Payments shall be
in amounts net of any such deductions or withholdings. Except to the extent otherwise specified,
nothing in this Section 6(g) shall be construed to require the Employer to make any payments to
compensate the Executive for any adverse tax effect associated with the Retention Bonus Payments or
for any deduction or withholding from any payment or benefit.

To be eligible for the Retention Bonus Payments set forth above, the Executive must meet the
following requirements (the “Retention Bonus Requirements”):

	 	•	 	The Executive must remain an active, full-time employee of the Employer from the date of
this Agreement as amended through the applicable date(s). Subject to the Executive’s right
to receive the Change in Control Payments under the terms described above, if the Executive
terminates the Executive’s employment with or without Good Reason, if the Employer
terminates the Executive’s employment with or without Cause, or if the Executive’s
employment terminates due to the Executive’s death or disability, the Executive’s rights to
participate in the Retention Bonus Plan as set forth in this Section 6(g) shall be
immediately terminated and the Executive will not be entitled to any of the Retention Bonus
Payments that the Executive has not already received; and
	 
	 	•	 	The Executive is required to comply with the terms of this Agreement.

For purposes of the Change in Control Payments, a “Change in Control” means the occurrence of any
of the following events:

	•	 	Merger or consolidation of the Employer, other than a merger or consolidation which would
result in the voting securities of the Employer outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity or the parent of such corporation) at least 50% of the
total voting power represented by the voting securities of the Employer or

3

 

	 	 	 	such surviving entity or parent of such corporation outstanding immediately after such
merger or consolidation;
	 
	 	•	 	The stockholders of the Employer approve an agreement for the sale or disposition by the
Employer of all or substantially all of the Employer’s assets; or
	 
	 	•	 	Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said
Act), directly or indirectly, of securities of the Employer representing 50% or more of the
total voting power represented by the Employer’s then outstanding voting securities (excluding
for this purpose the Employer or its Affiliates or any employee benefit plan of the
Employer).”

     2. Except as so amended, the Original Agreement in all other respects is hereby confirmed.

          IN WITNESS WHEREOF, this Amendment has been executed as a sealed instrument by the Employer,
by its duly authorized officer, and by the Executive, as of the date first written herein above.

	 	 	 	 	 
	 	 	EPIX PHARMACEUTICALS, INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Elkan Gamzu
	 

	 	 	 	 
	 

	 	 	 	[Name and Title]
	 
	 	 	 	 
	 	 	/s/ Chen Schor
	 	 	 
	 	 	Chen Schor

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]